The ASPiRATION study will be the first-of-its-kind in Australia to generate high quality, real world, clinical and medical data about the impact and value of comprehensive genomic profiling (CGP), precision medicine and personalised healthcare (PHC). The enhanced genomic profiling will assist in personalising patient care by matching patients to targeted treatments as early as possible to improve patient outcomes.

ASPiRATION will be delivered by Australian Genomic Cancer Medicine Centre (Omico), the Thoracic Oncology Group of Australasia (TOGA), and the NHMRC Clinical Trials Centre (CTC).

The Australian Government will commit $5 million towards the study through the Medical Research Future Fund (MRFF) while Roche will contribute $6.74 million, and access to Roche medicines via clinical trials.